Clinical Trials
13 trialsNCT01203722 2026-02-19
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT04083170 2025-01-01
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT02065869 2023-09-29
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT03733249 2023-09-26
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT02074436 2022-07-19
PROBLEMA
Emory University
Phase 2 Terminated
NCT02964325 2021-08-19
MIPLATE
Terumo BCTbio
Phase NA Terminated
NCT01010217 2020-03-25
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01251575 2019-12-09
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00997386 2019-09-09
ALBUM
University of Arizona
Phase 2 Completed
NCT01447914 2019-08-28
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00673114 2015-04-03
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Duke University
Phase 1/2 Completed
NCT00720629 2014-07-18
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00795132 2013-07-30
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
University of Utah
Phase 2 Completed